The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

BioSpace examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

A miracle drug just wiped out WeightWatchers International’s (WW) 60-year empire. Here’s how Ozempic disrupted the weight ...

Compounding pharmacies are supposed to stop producing the compounded versions of the popular weight loss medications now that ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...